Valeant effort

The $8.7 bln Bausch & Lomb deal is the biggest yet for the acquisitive pharmaceuticals group, but it comes with cost savings worth at least $5.6 bln. Investors added about as much to Valeant’s market value, giving it firepower to seek new targets. CEOs elsewhere should take note.